Tuberculosis and systemic lupus erythematosus: a case-control study in Mexico City
- 138 Downloads
To determine, among systemic lupus erythematosus patients, factors associated with active tuberculosis. We performed a case-control study, in a tertiary-care center in Mexico City. We defined cases as systemic lupus erythematosus patients with active tuberculosis and matched them 1:1 with systemic lupus erythematosus patients without tuberculosis (controls) by age, date of systemic lupus erythematosus diagnosis, and disease duration. We analyzed clinical variables, lupus disease activity (SLEDAI-2K), and accumulated damage (SLICC/ARC-DI). We performed a nonconditional logistic regression to determine factors associated with tuberculosis. We identified 72 tuberculosis cases among systemic lupus erythematosus patients, 58% were culture confirmed. Thirty-three percent (24/72) were pulmonary only, 47.2% (34/72) extrapulmonary only, and 19.4% both. After adjustment for age, gender, and socioeconomic status, SLEDAI-2K and SLICC/ARC-DI, a 1-year cumulative dose of prednisone ≥ 3 g (odds ratios (OR), 18.85; 95% confidence interval (95% CI), 6.91–51.45) was associated with tuberculosis, and the antimalarial treatment was protective (OR, 0.13; 95% CI, 0.04–0.36). Among systemic lupus erythematosus patients, cumulative dose of prednisone is associated with tuberculosis. Further research is required to elucidate the protective effect of antimalarial drugs for tuberculosis. Preventive strategies must be implemented in patients at risk.
KeywordsAccumulated damage Antimalarial drugs Disease activity Prednisone Systemic lupus erythematosus Tuberculosis
This work was supported by internal funding.
Compliance with ethical standards
This study was carried out in compliance with the Helsinki Declaration. The Institutional Review Board approval for this study was obtained from the Comité Institucional de Investigación Biomédica en Humanos (reference 1534). All collected data were anonymized before analysis.
- 5.Pelaez-Ballestas I, Sanin LH, Moreno-Montoya J, Alvarez-Nemegyei J, Burgos-Vargas R, Garza-Elizondo M, Rodriguez-Amado J, Goycochea-Robles MV, Madariaga M, Zamudio J, Santana N, Cardiel MH, Grupo de Estudio Epidemiologico de Enfermedades Musculo A (2011) Epidemiology of the rheumatic diseases in Mexico A study of 5 regions based on the COPCORD. J Rheumatol Suppl 86:3–8. https://doi.org/10.3899/jrheum.100951 CrossRefPubMedGoogle Scholar
- 16.Torres-Gonzalez P, Cervera-Hernandez ME, Martinez-Gamboa A, Garcia-Garcia L, Cruz-Hervert LP, Bobadilla-Del Valle M, Ponce-de Leon A, Sifuentes-Osornio J (2016) Human tuberculosis caused by Mycobacterium bovis: a retrospective comparison with Mycobacterium tuberculosis in a Mexican tertiary care Centre, 2000-2015. BMC Infect Dis 16(1):657. https://doi.org/10.1186/s12879-016-2001-5 CrossRefPubMedPubMedCentralGoogle Scholar
- 19.O'Garra A, Redford PS, McNab FW, Bloom CI, Wilkinson RJ, Berry MP (2013) The immune response in tuberculosis. Annu Rev Immunol 31:475–527. https://doi.org/10.1146/annurev-immunol-032712-095939 CrossRefPubMedGoogle Scholar
- 20.Rainsford KD, Parke AL, Clifford-Rashotte M, Kean WF (2015) Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. Inflammopharmacology 23(5):231–269. https://doi.org/10.1007/s10787-015-0239-y CrossRefPubMedGoogle Scholar
- 27.Kerkhoff AD, Meintjes G, Burton R, Vogt M, Wood R, Lawn SD (2016) Relationship between blood concentrations of hepcidin and anemia severity, mycobacterial burden, and mortality among patients with HIV-associated tuberculosis. J Infect Dis 213(1):61–70. https://doi.org/10.1093/infdis/jiv364 CrossRefPubMedGoogle Scholar